Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002978 | 0.88 | MEN1 (0.45) | MEN1KMT2ALMNASMN1; SMN2CYP3A4 | |
| SCHEMBL2023264 | 0.86 | MEN1 (0.44) | MEN1KMT2APDE5ADRD4BCHE | |
| SCHEMBL12413546 | 0.84 | HCRTR1 (0.52) | CYP3A4 | |
| SCHEMBL8272780 | 0.82 | ABCB1 (0.44) | MEN1KMT2A | |
| SCHEMBL15729288 | 0.82 | PARP1 (0.47) | MEN1KMT2ALMNASMN1; SMN2TSHR | |
| SCHEMBL8240557 | 0.80 | ALDH1A1 (0.42) | MEN1KMT2ALMNASMN1; SMN2DRD4 | |
| SCHEMBL8270478 | 0.79 | P2RX7 (0.45) | MEN1KMT2AP2RX7 | |
| SCHEMBL12582025 | 0.79 | ALDH1A1 (0.45) | MEN1KMT2ALMNASMN1; SMN2DRD4 | |
| SCHEMBL2026795 | 0.78 | PTGER2 (0.49) | MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2028806 | 0.78 | HCRTR1 (0.53) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | VAN WAGENEN BRADFORD | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166155-A1 | Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators | GRM1, GRIN1, GRM2 | MEN1 3002/4885KMT2A 3209/4885CNR2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.